MedPath

Use of Pre-operative Global Longitudinal Strain to Predict Post-operative Left Ventricular Dysfunction in Mitral Regurgitation Surgery

Completed
Conditions
Preserved Ventricular Ejection Fraction
Severe Mitral Regurgitation
Interventions
Other: Mitral regurgitation surgery such as mitral valve replacement or repair
Registration Number
NCT03968601
Lead Sponsor
University Hospital, Clermont-Ferrand
Brief Summary

Primary mitral regurgitation (MR) is the second most frequent valve disease requiring surgery and it is important to identify patients whose outcome could be improved with surgery by considering the risks and benefits.

The current guidelines recommend surgery in patients with symptomatic severe mitral regurgitation or in asymptomatic patients who develop early signs of left ventricular (LV) dysfunction as a result of the MR.

However, it remains difficult to determine optimal timing for surgery with the current guidelines.

Early-stage LV dysfunction with normal LVEF predicts post-operative LV decompensation and poor prognosis and longitudinal myocardial function is suitable for detection of minor myocardial damage in patients with MR.

Thus, inestigators want to study the value of LV global longitudinal strain (GLS) to predict postoperative LV dysfunction in patients with chronic severe MR and preserved pre-operative LVEF.

The principal aim is to prove that the optimal timing for surgery, in asymptomatic chronic severe primary MR with preserved LVEF, is before GLS alteration, and that investigators should not wait for LV dilatation of dysfunction.

Detailed Description

Primary mitral regurgitation (MR) is the second most frequent valve disease requiring surgery.

In these patients, mitral repair is associated with excellent outcomes in terms of post-operative left ventricular (LV) function, and long-term survival when performed before the onset of severe symptoms, LV dysfunction or dilatation, pulmonary hypertension, and atrial fibrillation.

Thus, it is important to identify patients whose outcome could be improved with surgery by considering the risks and benefits.

The current guidelines recommend surgery in patients with symptomatic severe mitral regurgitation or in asymptomatic patients who develop early signs of left ventricular (LV) dysfunction as a result of the MR. LV dysfunction has been defined as LV ejection fraction (EF) 30% to 60% and/or LV end-systolic dimension (ESD) up to 45 mm.

However, it remains difficult to determine optimal timing for surgery with the current guidelines.

LVEF and LVESD, parameters proposed in the guideline, are difficult to interpret due to the influence of hemodynamic parameters of MR.

In asymptomatic patients who consider undergoing surgery, LVESD is rarely more than 45 mm.

In addition, LVEF in patients with severe MR often remains normal or higher, and subclinical LV dysfunction might be masked due to MR lowering of LV afterload.

Early-stage LV dysfunction with normal LVEF predicts post-operative LV decompensation and poor prognosis.

Therefore, it is a great challenge to identify potential LV dysfunction at an early stage and to perform surgery to prevent the development of irreversible LV dysfunction in patients with chronic severe MR.

Longitudinal myocardial function has been considered more sensitive than radial function and is therefore suitable for detection of minor myocardial damage in patients with MR.

A 2017 study proved that pre-operative GLS ≤ -18.4% can predict a preserved post-operative LVEF \>50%.

Therefore, invetsigators want to study the value of LV global longitudinal strain (GLS) to predict postoperative LV dysfunction in patients with chronic severe MR and preserved pre-operative LVEF.

The principal aim is to prove that the optimal timing for surgery, in asymptomatic chronic severe primary MR with preserved LVEF, is before GLS alteration, and that investigators should not wait for LV dilatation of dysfunction.

Thus, investigators will recruit patients before surgery, measuring GLS during pre-operative conventional echography, and follow-up patients at 8 days, 1 month and 6 months to determine whether LVEF is preserved or not.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
79
Inclusion Criteria
  • Stage 3 or 4, primary and chronic mitral regurgitation, going for a planned surgery, with pre-operative left ventricular ejection fraction > 60% and left ventricular end-systolic dimension < 45mm.
  • Able to consent.
  • With a National Social Security number.
Exclusion Criteria

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
cohorte 1Mitral regurgitation surgery such as mitral valve replacement or repairSevere primary chronic mitral regurgitation with preserved left ventricular ejection fraction.
Primary Outcome Measures
NameTimeMethod
Pre-operative global longitudinal strain rate among patients going for mitral surgery.During pre-operative visit

Pre-operative global longitudinal strain in patients going for mitral regurgitation surgery with preserved LVEF, measured by echocardiography.

Secondary Outcome Measures
NameTimeMethod
Measure Quality of life: Minnesota Living with Heart Failure Questionnaire (MLHFQ)This test will be realized during pre-operative visit and repeated at 1-month and 6-months visits.

Minnesota Living with Heart Failure Questionnaire (MLHFQ), evaluating : legs swelling, walking and working capacity, presence of sleeping or breathing disorders, difficulties for sport, hobbies or relationships, side effects from medications, psychologic and economic impact of the disease. The total score goes from 0 (best quality of life) to 105 (worse impact).

DyspnoeaThis test will be realized during pre-operative visit and repeated at 8-days, 1-month and 6-months visits.

Use of the New York Heart Association (NYHA) Functional Classification.

Cardiovascular mortality, as the number of death from cardiovascular disease during the follow upAt 8 days, 1-month and 6-months

Death by myocardial ischemia or infarction, heart failure, cardiac arrest, or cerebrovascular accident.

Pre-operative right ventricular function (measured by Tricuspid Annular Plane Systolic Excursion - TAPSE, Peak Systolic Velocity in DTI mode and Fractional Area Change).These measures will be realized during pre-operative visit and repeated at 1-month and 6-months visits

We aim to determine whether or not right ventricular function (measured by Tricuspid Annular Plane Systolic Excursion - TAPSE, Peak Systolic Velocity in DTI mode and Fractional Area Change) can have an impact on post-operative LVEF in patients going for mitral regurgitation surgery.

Pre-operative pulmonary arterial pressure determined by tricuspid regurgitation peak velocityThese measures will be realized during pre-operative visit and repeated at 1-month and 6-months visits.

Ithe aim is to determine whether or not pulmonary hypertension (determined by tricuspid regurgitation peak velocity) can have an impact on post-operative LVEF in patients going for mitral regurgitation surgery.

Left ventricular ejection indexDuring pre-operative visit.

Impact of this novel left ventricular ejection index (defined as indexed left ventricular end-systolic diameter divided by left ventricular outflow tract time-velocity integral) on post-operative left ventricular dysfunction, compared with global longitudinal strain.

All-cause mortality, as the total number of death during the follow-upAt 8 days, 1-month and 6-months

all death reported

Number of patients hospitalized due to heart failure during the follow upAt 8 days, 1-month and 6-months

all re-hospitalisation reported

Functional impact in terms of walking distance.This test will be realized during pre-operative visit and repeated at 1-month and 6-months visits.

6 Minute Walk Distance

Left ventricular functionThis test will be realized during pre-operative visit and repeated at 8-days, 1-month and 6-months visits.

Left ventricular ejection fraction by Simpson method.

Trial Locations

Locations (1)

CHU de Clermont-Ferrand

🇫🇷

Clermont-Ferrand, France

© Copyright 2025. All Rights Reserved by MedPath